Pediatric rheumatology

Spatial transcriptomic analysis of muscle biopsy from patients with treatment-naive juvenile dermatomyositis reveals mitochondrial abnormalities despite disease-related interferon-driven signature

Ann Rheum DisPublished Mechanistic study

Authors' conclusion

This study highlights mitochondrial dysfunction as a consistent pathological feature in JDM muscle, which may be independent of interferon-driven inflammation.

Study context

Population
Muscle biopsies from patients with treatment-naive juvenile dermatomyositis (JDM) and age-matched controls; validation in 19 JDM cases and a bulk RNAseq dataset of 4 JDM cases
Participants
3 vs 3
Comparison
Treatment-naive JDM muscle vs healthy paediatric muscle
  • JDMn = 3
  • Controlsn = 3reference
Methodological detailsspatial transcriptomics (Nanostring GeoMx Digital Spatial Profiler), age-matched controls, validation by immunohistochemistry, chemical stains and bulk RNAseq
  • Spatial transcriptomics (Nanostring GeoMx Digital Spatial Profiler)
  • Age-matched controls
  • Validation by immunohistochemistry, chemical stains and bulk RNAseq

Main finding

As reported in the abstract

  • Significant interferon pathway activation and mitochondrial dysfunction in JDM muscle vs controls
  • 15-gene interferon signature significantly elevated in JDM muscle and macrophage-enriched regions, correlating with clinical weakness
  • Mitochondrial dysregulation (downregulated respiratory chain pathways) present regardless of interferon activity or muscle strength
  • Interferon-driven and mitochondrial signatures replicated in independent RNAseq dataset; lack of association between interferon signature and mitochondrial dysregulation validated in 19 cases by conventional staining
  • Distinct transcriptomic profiles between JDM and controls, and between JDM patients with varying clinical phenotypes

Original publication

Spatial transcriptomic analysis of muscle biopsy from patients with treatment-naive juvenile dermatomyositis reveals mitochondrial abnormalities despite disease-related interferon-driven signature. Ann Rheum Dis. Published 9 August 2025. doi:10.1016/j.ard.2025.07.015

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.